Neuronal communication and neurological function rely on chemical signaling across a narrow extracellular space known as the synaptic cleft.  Proteins positione

The Institute for Protein Innovation (IPI), a nonprofit research institute dedicated to advancing protein science, today celebrates the extension of its

The story of the discovery of these molecules 50 years ago shows how the free exchange of ideas can lead to life-changing treatments.

YouTube video by Progress, Potential, and Possibilities

Collaboration aims to advance next-generation therapeutics and vaccines

The story of the discovery of these molecules 50 years ago shows how the free exchange of ideas can lead to life-changing treatments.

Antibodies Market Industry is expected to grow from 173.28(USD Billion) in 2024 to 300.0(USD Billion) by 2035. The Antibodies Market CAGR (growth rate) is expected to be around 5.12% during the foreca...

Long COVID has afflicted tens of millions globally leaving many previously-healthy persons severely and indefinitely debilitated. The objective here w…

Background: The rapid evolution of SARS-CoV-2 imposed a huge challenge on disease control. Immune evasion caused by genetic variations of the SARS-CoV-2 spike protein’s immunogenic epitopes affects the efficiency of monoclonal antibody–based therapy of COVID-19. Therefore, a rapid method is needed to evaluate the efficacy of the available monoclonal antibodies against the new emerging variants or potential novel variants. Objective: The aim of this study is to develop a rapid computational method to evaluate the neutralization power of anti–SARS-CoV-2 monoclonal antibodies against new SARS-CoV-2 variants and other potential new mutations. Methods: The amino acid sequence of the extracellular domain of the spike proteins of the severe acute respiratory syndrome coronavirus (GenBank accession number YP_009825051.1) and SARS-CoV-2 (GenBank accession number YP_009724390.1) were used to create computational 3D models for the native spike proteins. Specific mutations were introduced to the curated sequence to generate the different variant spike models. The neutralization potential of sotrovimab (S309) against these variants was evaluated based on its molecular interactions and Gibbs free energy in comparison to a reference model after molecular replacement of the reference receptor-binding domain with the variant’s receptor-binding domain. Results: Our results show a loss in the binding affinity of the neutralizing antibody S309 with both SARS-CoV and SARS-CoV-2. The binding affinity of S309 was greater to the Alpha, Beta, Gamma, and Kappa variants than to the original Wuhan strain of SARS-CoV-2. However, S309 showed a substantially decreased binding affinity to the Delta and Omicron variants. Based on the mutational profile of Omicron subvariants, our data describe the effect of the G339H and G339D mutations and their role in escaping antibody neutralization, which is in line with published clinical reports. Conclusions: This method is rapid, applicable, and of interest to adapt the use of therapeutic antibodies to the treatment of emerging variants. It could be applied to antibody-based treatment of other viral infections.

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe symptoms linked to RSV and other respiratory viruses. Hospitalizations for R...

As the cover so boldly suggests, we’re talking ‘women in pharma’. Progress, ambitions, direction, understanding and essence. Indeed, this edition focuses on the dimensions of difference that only wome...